Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company"s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.
Website: unither.com



Growth: Good revenue growth rate 23.0%, there is acceleration compared to average historical growth rates 18.8%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +48.7%. On average the margin is decreasing unsteadily. Gross margin is high, +88.9%. In the last quarter the company beat the estimated EPS, +7.5%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.1 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 11.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 117.3% higher than minimum and 11.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.9x by EV / Sales multiple , the company can be 11.7% overvalued

Insiders: For the last 3 months insiders sold company shares on $61.8 mln (-0.372% of cap.)

Key Financials (Download financials)

Ticker: UTHR
Share price, USD:  (0.0%)361.1
year average price 321.96  


year start price 223.58 2024-02-26

min close price 223.58 2024-02-26

max close price 410.00 2024-11-08

current price 361.10 2025-02-24
Common stocks: 45 500 000

Dividend Yield:  0.0%
FCF Yield LTM: 11.2%
EV / LTM EBITDA: 11.4x
EV / EBITDA annualized: 10.5x
Last revenue growth (y/y):  +23.0%
Last growth of EBITDA (y/y):  +6.5%
Historical revenue growth:  +18.8%
Historical growth of EBITDA:  +40.8%
EV / Sales: 5.5x
Margin (EBITDA LTM / Revenue): 48.7%
Fundamental value created in LTM:
Market Cap ($m): 16 430
Net Debt ($m): -1 154
EV (Enterprise Value): 15 276
Price to Book: 2.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-02-13zacks.com

Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?

2025-02-07zacks.com

UTHR or ZTS: Which Is the Better Value Stock Right Now?

2025-01-08zacks.com

UTHR vs. STVN: Which Stock Is the Better Value Option?

2024-12-25zacks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

2024-11-15seekingalpha.com

United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy

2024-11-04zacks.com

United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?

2024-11-01zacks.com

United Therapeutics Q3 Earnings & Sales Beat Estimates

2024-10-30seekingalpha.com

United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript

2024-10-30zacks.com

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings

2024-10-30zacks.com

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-30 2024-07-31 2024-05-01 2024-02-21 2023-11-01 2023-08-02 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 749M 715M 678M 615M 609M 597M 507M 492M 516M
costOfRevenue 83M 78M 73M 71M 70M 64M 52M 56M 37M
grossProfit 666M 637M 605M 544M 539M 532M 455M 436M 479M
grossProfitRatio 0.889 0.891 0.892 0.884 0.885 0.893 0.897 0.886 0.928
researchAndDevelopmentExpenses 104M 140M 104M 151M 85M 89M 83M 94M 66M
generalAndAdministrativeExpenses 199M 152M 121M 108M 107M 110M 70M 143M 81M
sellingAndMarketingExpenses 21M 25M 23M 24M 21M 20M 17M 23M 17M
sellingGeneralAndAdministrativeExpenses 219M 178M 144M 132M 128M 130M 87M 166M 98M
otherExpenses 0 800 000 2M -600 000 -5M -600 000 -8M -5M 0
operatingExpenses 323M 317M 249M 284M 212M 219M 170M 260M 165M
costAndExpenses 406M 395M 321M 355M 282M 283M 223M 316M 202M
interestIncome 50M 46M 54M 51M 45M 37M 29M 21M 13M
interestExpense 10M 12M 13M 15M 16M 15M 14M 12M 9M
depreciationAndAmortization 19M 19M 15M 43 812 40M 37M 35M 16M 20M
ebitda 418M 339M 427M 324M 367M 350M 319M 191M 335M
ebitdaratio 0.558 0.474 0.63 0.527 0.603 0.587 0.629 0.389 0.648
operatingIncome 343M 320M 356M 260M 327M 313M 284M 176M 314M
operatingIncomeRatio 0.458 0.447 0.526 0.423 0.537 0.525 0.561 0.357 0.609
totalOtherIncomeExpensesNet 46M 35M 2M -600 000 -5M -600 000 8M 3M -2M
incomeBeforeTax 389M 355M 399M 295M 352M 335M 292M 179M 313M
incomeBeforeTaxRatio 0.519 0.497 0.588 0.481 0.577 0.562 0.576 0.364 0.606
incomeTaxExpense 80M 77M 92M 78M 84M 76M 51M 47M 73M
netIncome 309M 278M 307M 217M 268M 259M 241M 132M 239M
netIncomeRatio 0.413 0.389 0.452 0.353 0.439 0.435 0.475 0.269 0.464
eps 6.93 6.26 6.52 4.62 5.71 5.53 5.2 2.88 5.26
epsdiluted 6.39 5.85 6.17 4.36 5.38 5.24 4.86 2.67 4.91
weightedAverageShsOut 45M 44M 47M 47M 47M 47M 46M 46M 46M
weightedAverageShsOutDil 48M 48M 50M 50M 50M 50M 50M 49M 49M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-30 2024-07-31 2024-05-01 2024-02-21 2023-11-01 2023-08-02 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 554M 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M
shortTermInvestments 1 773M 1 616M 1 456M 1 786M 3 829M 3 635M 1 700M 1 878M 1 649M
cashAndShortTermInvestments 3 327M 2 972M 2 708M 2 994M 4 936M 4 703M 2 863M 4 155M 2 616M
netReceivables 342M 291M 307M 279M 259M 273M 135M 220M 232M
inventory 147M 137M 120M 112M 104M 103M 103M 102M 91M
otherCurrentAssets 185M 221M 113M 166M 1 988M 1 770M 93M 219M 118M
totalCurrentAssets 4 000M 3 620M 3 249M 3 551M 3 459M 3 213M 3 193M 3 380M 3 056M
propertyPlantEquipmentNet 1 157M 1 095M 1 074M 1 045M 992M 939M 897M 862M 841M
goodwill 0 0 0 34M 0 0 0 28M 28M
intangibleAssets 112M 115M 115M 81M 44M 0 0 17M 17M
goodwillAndIntangibleAssets 112M 115M 115M 114M 44M 45M 45M 45M 45M
longTermInvestments 1 279M 1 359M 1 492M 1 910M 2 061M 2 024M 1 766M 1 316M 1 444M
taxAssets 391M 396M 396M 395M 326M 326M 322M 328M 281M
otherNonCurrentAssets 184M 139M 169M 152M 142M 135M 125M 114M 115M
totalNonCurrentAssets 3 123M 3 104M 3 247M 3 616M 3 565M 3 468M 3 153M 2 664M 2 725M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M
accountPayables 364M 325M 305M 6M 333M 0 0 4M 0
shortTermDebt 400M 400M 400M 400M 300M 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 -305M 328M -333M 0 0 0 0
otherCurrentLiabilities 110M 107M 461M 71M 444M 370M 325M 339M 316M
totalCurrentLiabilities 873M 832M 861M 804M 744M 370M 325M 343M 316M
longTermDebt 0 100M 200M 300M 500M 800M 800M 800M 800M
deferredRevenueNonCurrent 0 0 0 -42M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 42M 0 0 0 0 0
otherNonCurrentLiabilities 149M 94M 97M 78M 67M 100M 98M 105M 904M
totalNonCurrentLiabilities 149M 194M 297M 378M 567M 900M 898M 905M 904M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 33M 0 0 0 0 0
totalLiabilities 1 022M 1 026M 1 157M 1 182M 1 312M 1 270M 1 223M 1 248M 1 219M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000
retainedEarnings 6 921M 6 612M 6 334M 6 027M 5 810M 5 542M 5 283M 5 042M 4 910M
accumulatedOtherComprehensiveIncomeLoss 7M -15M -16M -13M -44M -51M -39M -56M -84M
othertotalStockholdersEquity -828M -900M -981M -30M -55M -82M -122M -191M -265M
totalStockholdersEquity 6 101M 5 697M 5 338M 5 985M 5 712M 5 411M 5 123M 4 797M 4 562M
totalEquity 6 101M 5 697M 5 338M 5 985M 5 712M 5 411M 5 123M 4 797M 4 562M
totalLiabilitiesAndStockholdersEquity 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M
totalInvestments 3 052M 2 975M 1 492M 3 696M 2 061M 2 024M 1 766M 3 194M 3 093M
totalDebt 400M 500M 600M 700M 500M 800M 800M 800M 800M
netDebt -1 154M -856M -652M -508M -608M -267M -364M -161M -167M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-10-30 2024-07-31 2024-05-01 2024-02-21 2023-11-01 2023-08-02 2023-05-03 2023-02-22 2022-11-02
acceptedDate 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 309M 278M 307M 217M 268M 259M 241M 132M 239M
depreciationAndAmortization 19M 19M 15M 14M 13M 13M 13M 13M 13M
deferredIncomeTax 0 -4M 0 77M -3M -3M 0 0 0
stockBasedCompensation 42M 50M 26M 17M 21M 14M -12M 65M -2M
changeInWorkingCapital 13M -109M 40M -92M 11M -139M 127M -88M -7M
accountsReceivables -51M 17M -28M -20M 14M -138M 86M 11M -58M
inventory -11M -15M -9M -7M -3M -1 000 000 -3M -14M -600 000
accountsPayables 33M 26M 2M -23M 4M 78M 3M 31M 0
otherWorkingCapital 42M -136M 76M -41M -4M -78M 41M -117M 52M
otherNonCashItems -6M 54M -11M -5M 36M -37M 6M 6M 16M
netCashProvidedByOperatingActivities 377M 232M 377M 151M 346M 106M 375M 128M 259M
investmentsInPropertyPlantAndEquipment -77M -45M -38M -79M -66M -45M -41M -40M -69M
acquisitionsNet 0 0 0 -89M 237M 179M 0 9M 0
purchasesOfInvestments -408M -231M -529M -308M -645M -672M -890M -431M -270M
salesMaturitiesOfInvestments 387M 197M 1 307M 527M 408M 493M 710M 269M 246M
otherInvestingActivites -18M -400 000 -4M -9M -248M -183M 0 4M -2M
netCashUsedForInvestingActivites -115M -80M 735M 42M -313M -227M -221M -189M -94M
debtRepayment -100M -100M -100M -100M 0 0 0 -1 585M 0
commonStockIssued 0 0 4M 7M 8M 0 61M 88M 0
commonStockRepurchased -400 000 -12M -1 000M -100 000 -200 000 0 -14M 11M -300 000
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 36M 64M -14M 7M -200 000 25M 700 000 1 541M 7M
netCashUsedProvidedByFinancingActivities -64M -48M -1 068M -93M 8M 25M 49M 56M 7M
effectOfForexChangesOnCash 0 0 0 -107M 0 107M 0 0 0
netChangeInCash 198M 104M 44M 100M 40M -96M 202M -6M 172M
cashAtEndOfPeriod 1 554M 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M
cashAtBeginningOfPeriod 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M 795M
operatingCashFlow 377M 232M 377M 151M 346M 106M 375M 128M 259M
capitalExpenditure -77M -45M -38M -79M -66M -45M -41M -40M -69M
freeCashFlow 301M 187M 338M 72M 281M 62M 334M 89M 190M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-30 10:30 ET
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
2024-10-23 11:00 ET
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
2024-10-23 10:30 ET
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
2024-09-24 11:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
2024-09-10 11:00 ET
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
2024-08-28 11:00 ET
United Therapeutics Corporation to Present at Upcoming Investor Conferences
2024-07-31 10:30 ET
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
2024-07-24 11:00 ET
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
2024-07-10 11:00 ET
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
2024-06-27 11:00 ET
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
2024-06-05 11:00 ET
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-01 10:30 ET
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
2024-04-24 13:00 ET
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
2024-04-24 11:00 ET
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
2024-04-16 11:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
2024-03-26 11:00 ET
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
2024-03-25 11:00 ET
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
2024-03-25 11:00 ET
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
2024-03-05 11:00 ET
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
2024-02-27 11:00 ET
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
2024-02-21 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 10:55 ET
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
2024-02-14 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024
2023-12-29 11:00 ET
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-07 11:00 ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024
2023-11-01 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2023 Financial Results
2023-10-31 10:05 ET
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis
2023-10-31 10:00 ET
United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023
2023-10-25 10:00 ET
United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023
2023-09-22 18:15 ET
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
2023-09-12 10:00 ET
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
2023-09-01 10:00 ET
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-02 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
2023-07-26 10:00 ET
United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023
2023-07-24 15:45 ET
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation
2023-06-14 10:00 ET
United Therapeutics Unveils Net Zero Energy Distribution Center
2023-05-03 10:00 ET
United Therapeutics Corporation Reports First Quarter 2023 Financial Results
2023-04-26 10:00 ET
United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023
2023-04-18 10:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings
2023-03-06 21:30 ET
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
2023-02-28 11:00 ET
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
2023-02-22 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-15 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023
2023-01-02 11:00 ET
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-08 11:00 ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2023
2022-11-02 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
2022-11-01 10:00 ET
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
2022-10-31 10:00 ET
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
2022-10-26 10:00 ET
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
2022-10-14 10:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
2022-10-11 10:00 ET
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
2022-09-12 21:00 ET
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
2022-08-31 22:40 ET
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
2022-08-24 10:00 ET
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
2022-08-03 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
2022-07-27 10:00 ET
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
2022-06-03 20:30 ET
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
2022-05-24 10:00 ET
United Therapeutics Announces FDA Approval of Tyvaso DPI™
2022-05-04 10:00 ET
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
2022-04-29 10:00 ET
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
2022-04-27 10:00 ET
United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022
2022-04-06 10:00 ET
United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation
2022-03-08 11:00 ET
United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference
2022-03-01 11:00 ET
United Therapeutics Corporation to Present at the Cowen 42nd Annual Health Care Conference
2022-02-24 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-21 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022
2022-01-21 11:00 ET
United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs
2021-12-30 11:00 ET
United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst
2021-12-03 11:00 ET
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
2021-11-03 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2021 Financial Results
2021-11-01 10:00 ET
United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference
2021-10-27 20:20 ET
Volumetric to Be Acquired by 3D Systems to Advance Tissue and Organ Manufacturing
2021-10-27 10:00 ET
United Therapeutics Corporation To Report Third Quarter 2021 Financial Results Before The Market Opens On Wednesday, November 3, 2021
2021-10-21 10:00 ET
United Therapeutics Details New Data Presented at CHEST Annual Meeting 2021
2021-10-18 10:00 ET
United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application
2021-10-11 10:00 ET
United Therapeutics to Present New Data at CHEST Annual Meeting 2021
2021-09-30 20:30 ET
United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval
2021-09-10 10:00 ET
United Therapeutics Releases its Annual Corporate Responsibility Report
2021-08-25 10:00 ET
United Therapeutics Partners with Former NFL Player Devon Still and His Daughter Leah to Launch "Braving NeuroBLASToma" in Honor of Childhood Cancer Awareness Month
2021-08-04 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
2021-08-03 10:00 ET
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
2021-07-28 10:00 ET
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
2021-06-30 10:00 ET
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
2021-06-07 10:00 ET
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
2021-06-03 10:00 ET
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
2021-05-25 10:00 ET
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
2021-05-05 10:00 ET
United Therapeutics Corporation Reports First Quarter 2021 Financial Results
2021-04-26 10:00 ET
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021
2021-04-01 10:00 ET
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
2021-03-24 10:00 ET
United Therapeutics Corporation To Present At The 10th Annual J.P. Morgan Napa Valley Forum
2021-03-09 11:00 ET
United Therapeutics Corporation To Present At The Oppenheimer 31st Annual Healthcare Conference
2021-02-24 21:30 ET
United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference
2021-02-24 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter And Full Year 2020 Financial Results
2021-02-17 11:00 ET
United Therapeutics Corporation To Report Fourth Quarter And Full Year 2020 Financial Results Before The Market Opens On Wednesday, February 24, 2021
2021-02-10 11:00 ET
United Therapeutics Announces Commercial Launch Of The Remunity® Pump For Remodulin®
2021-01-28 11:00 ET
United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
2021-01-13 22:01 ET
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
2021-01-04 11:00 ET
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference
2020-12-28 11:00 ET
United Therapeutics Announces Agreement To Acquire Priority Review Voucher
2020-12-09 11:00 ET
United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
2020-11-24 11:00 ET
United Therapeutics Releases Its First Corporate Responsibility Report
2020-11-10 11:00 ET
United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference
2020-11-02 10:55 ET
United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference
2020-10-28 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
2020-10-22 10:00 ET
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
2020-10-21 10:00 ET
United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020
2020-10-15 10:00 ET
United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020
2020-09-21 11:00 ET
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant
2020-09-16 10:00 ET
United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2020-09-11 10:00 ET
United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors
2020-08-17 10:00 ET
United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease
2020-08-05 10:00 ET
United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference
2020-07-29 10:00 ET
United Therapeutics Corporation Reports Second Quarter 2020 Financial Results
2020-07-23 10:00 ET
United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia
2020-07-22 10:00 ET
United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020
2020-06-17 10:00 ET
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
2020-06-05 10:00 ET
United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents
2020-05-26 10:00 ET
United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference
2020-05-06 10:00 ET
United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020
2020-04-29 10:00 ET
United Therapeutics Corporation Reports First Quarter 2020 Financial Results
2020-04-23 10:00 ET
United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension
2020-04-22 10:00 ET
United Therapeutics Corporation to Report First Quarter 2020 Financial Results Before the Market Opens on Wednesday, April 29, 2020
2020-02-26 11:00 ET
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-25 11:00 ET
United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference
2020-02-24 11:16 ET
United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®
2020-02-24 11:00 ET
United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints
2020-02-19 11:00 ET
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020
2020-02-04 22:00 ET
United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen
2020-02-03 11:00 ET
United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint
2019-10-30 10:00 ET
United Therapeutics Corporation Reports Third Quarter 2019 Financial Results
2019-10-23 10:00 ET
United Therapeutics Corporation to Report Third Quarter 2019 Financial Results Before the Market Opens on Wednesday, October 30, 2019
2019-10-21 10:00 ET
United Therapeutics Announces FDA Approval Of Updated Label For Orenitram Reflecting Results Of FREEDOM-EV Study
2019-09-11 10:00 ET
United Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review
2019-08-06 10:00 ET
United Therapeutics Corporation To Present At 2019 Wedbush PacGrow Healthcare Conference
2019-07-24 10:00 ET
United Therapeutics Corporation To Report Second Quarter 2019 Financial Results Before The Market Opens On Wednesday, July 31, 2019
2019-06-05 10:00 ET
United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference
2019-05-28 10:00 ET
United Therapeutics Corporation To Present at Jefferies 2019 Healthcare Conference
2019-04-29 10:00 ET
United Therapeutics Announces FDA Approval Of XPS(TM) And Steen Solution(TM) Used To Perform Centralized Ex-Vivo Lung Perfusion Services
2019-04-24 10:00 ET
United Therapeutics Corporation To Report First Quarter 2019 Financial Results Before The Market Opens On Wednesday, May 1, 2019
2019-04-18 02:52 ET
United Therapeutics Issues Statement In Response To Meritless Lawsuit
2019-04-08 10:00 ET
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
2019-03-12 10:00 ET
United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference

SEC forms

Show financial reports only

SEC form 8
2024-10-30 06:34 ET
United Therapeutics published news for 2024 q3
SEC form 8
2024-10-30 06:34 ET
United Therapeutics published news for 2024 q3
SEC form 10
2024-10-30 06:32 ET
United Therapeutics reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
United Therapeutics published news for 2024 q3
SEC form 8
2024-07-31 06:33 ET
United Therapeutics published news for 2024 q2
SEC form 8
2024-07-31 06:33 ET
United Therapeutics published news for 2024 q2
SEC form 10
2024-07-31 06:31 ET
United Therapeutics reported for 2024 q2
SEC form 10
2024-07-31 00:00 ET
United Therapeutics published news for 2024 q2
SEC form 8
2024-05-01 06:34 ET
United Therapeutics published news for 2024 q1
SEC form 8
2024-05-01 06:34 ET
United Therapeutics published news for 2024 q1
SEC form 10
2024-05-01 06:32 ET
United Therapeutics reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
United Therapeutics published news for 2024 q1
SEC form 8
2024-02-21 06:05 ET
United Therapeutics published news for 2023 q4
SEC form 8
2024-02-21 06:05 ET
United Therapeutics reported for 2023 q4
SEC form 8
2024-02-21 06:05 ET
United Therapeutics published news for 2023 q4
SEC form 10
2024-02-21 06:03 ET
United Therapeutics reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
United Therapeutics published news for 2023 q4
SEC form 8
2023-11-01 06:05 ET
United Therapeutics published news for 2023 q3
SEC form 10
2023-11-01 06:03 ET
United Therapeutics reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
United Therapeutics published news for 2023 q3
SEC form 6
2023-08-02 06:05 ET
United Therapeutics published news for 2023 q2
SEC form 10
2023-08-02 06:02 ET
United Therapeutics reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
United Therapeutics published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-07-24 16:30 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-07-14 16:31 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-06-28 06:47 ET
United Therapeutics published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
United Therapeutics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
United Therapeutics published news for 2023 q1
SEC form 6
2023-03-31 16:30 ET
United Therapeutics published news for 2022 q4
SEC form 6
2023-02-22 06:06 ET
United Therapeutics published news for 2022 q4
SEC form 10
2023-02-22 06:03 ET
United Therapeutics reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
United Therapeutics reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
United Therapeutics reported for 2022 q4
SEC form 6
2023-01-09 06:03 ET
United Therapeutics published news for 2022 q4
SEC form 6
2022-11-02 06:05 ET
United Therapeutics published news for 2022 q3
SEC form 10
2022-11-02 06:03 ET
United Therapeutics reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
United Therapeutics reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
United Therapeutics reported for 2022 q3
SEC form 6
2022-10-11 07:15 ET
United Therapeutics published news for 2022 q3
SEC form 6
2022-09-20 06:00 ET
United Therapeutics published news for 2022 q2
SEC form 6
2022-09-01 06:01 ET
United Therapeutics published news for 2022 q2
SEC form 6
2022-08-03 06:06 ET
United Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 06:03 ET
United Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
United Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
United Therapeutics reported for 2022 q2
SEC form 6
2022-06-28 17:08 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-05-24 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 06:08 ET
United Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 06:04 ET
United Therapeutics reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
United Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
United Therapeutics reported for 2022 q1
SEC form 6
2022-04-29 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-04-22 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-04-01 06:13 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-02-24 06:09 ET
United Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 06:05 ET
United Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
United Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
United Therapeutics published news for 2021 q4
SEC form 6
2022-01-18 06:01 ET
United Therapeutics published news for 2021 q4
SEC form 6
2021-12-27 06:02 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-11-03 06:07 ET
United Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 06:03 ET
United Therapeutics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
United Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-10-18 06:01 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-10-01 06:01 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-08-19 06:00 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 06:13 ET
United Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 06:04 ET
United Therapeutics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
United Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-07-14 06:15 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-06-25 16:30 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-23 06:01 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-16 06:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-07 06:01 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-03 06:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 06:17 ET
United Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 06:10 ET
United Therapeutics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
United Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 06:06 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-19 06:02 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-01 06:03 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-03-03 06:02 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 06:09 ET
United Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 06:07 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-10 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-05 06:05 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-28 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-22 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 17:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2020-12-28 06:08 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-12-09 06:00 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-12-02 06:01 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 06:21 ET
United Therapeutics published news for 2020 q3
SEC form 10
2020-10-28 06:12 ET
United Therapeutics published news for 2020 q3